Young-Onset Colon Cancer and Recurrence Risk By Gene Expression
Menée à partir de données portant sur 20 478 patients atteints d'un cancer du côlon de stade II à IIIA/B, cette étude analyse, en fonction de catégories d'âge et du stade de la tumeur, la distribution des scores de récidive basés sur l'expression d'un panel de 12 gènes ou sur l'expression de chacun de ces gènes
The incidence and mortality from colorectal cancer in younger adults (<55 years) is increasing. We reviewed the complete database of a gene-expression test, Oncotype DX Colon Recurrence Score® test, to determine age-related differences in Recurrence Score® (RS) and single-gene results (7 cancer-related of the 12-gene assay). We included 20,478 Stage II & III A/B colon cancer patients submitted to Genomic Health. RS results were grouped by low, intermediate, and high risk groups. Single-gene scores were described using median and interquartile range. Seventy-two and a half percent of all patients and 72.6% of those <40 years had low risk RS. Comparing older versus younger patients, RS or single-gene expression did not differ by age group or stage. Young-onset colon cancer does not differ by expression of the RS component genes. Most patients with stage II/III colon cancer have low-risk disease as measured by the 12-gene assay, regardless of age.
Journal of the National Cancer Institute , article en libre accès, 2019